IP Library › Granted Patent US 12,702,361
Granted Patent B2
US 12,702,361 · App. 18/179,594 · Granted Aug 11, 2026

Systems and methods for dynamically and intelligently monitoring a host's glycemic condition after an alert is triggered

Inventors: Hari Hampapuram (Beaverton, OR); Anna Leigh Davis (Cardiff by the Sea, CA); Naresh C. Bhavaraju (San Diego, CA); Apurv Ullas Kamath (San Diego, CA); Claudio Cobelli (Padua, IT); Giovanni Sparacino (Padua, IT); Andrea Facchinetti (Padua, IT); Chiara Zecchin (Pernumia, IT)
Assignee: Dexcom, Inc.
A61B5/746A61B5/0004A61B5/0022A61B5/0031A61B5/14503A61B5/14532A61B5/4848A61B5/4866A61B5/7221A61B5/7275A61B5/002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,702,361
App. No.
18/179,594
Filed
Mar 7, 2023
Granted
Aug 11, 2026
Kind
B2
Art Unit
2686
USPC
600/365
Abstract

Systems and methods for providing sensitive and specific alarms indicative of glycemic condition are provided herein. In an embodiment, a method of processing sensor data by a continuous analyte sensor includes: evaluating sensor data using a first function to determine whether a real time glucose value meets a first threshold; evaluating sensor data using a second function to determine whether a predicted glucose value meets a second threshold; activating a hypoglycemic indicator if either the first threshold is met or if the second threshold is predicted to be met; and providing an output based on the activated hypoglycemic indicator.

Claims (69)

1 . A method for activating glycemic indicators, the method comprising:

evaluating a selection of glucose sensor data using a first function to determine whether a real time glucose value meets or crosses a user settable real time threshold value;

evaluating the same selection of glucose sensor data using a second function different from the first function to determine whether a predicted glucose value meets or crosses a predictive threshold value within a fixed prediction horizon, wherein the user settable real time threshold value is different from the predictive threshold value;

providing a first output including a first glycemic indicator when the user settable real time threshold value is met or crossed; and

providing a second output including a second glycemic indicator when the predicted glucose value meets or crosses the predictive threshold value within the fixed prediction horizon.

2 . The method of claim 1 , wherein the fixed prediction horizon is not settable by a user.

3 . The method of claim 1 , wherein the fixed prediction horizon is preset.

4 . The method of claim 3 , wherein:

the selection of glucose sensor data is a value representative of one or more data points averaged over a predetermined time period.

5 . The method of claim 1 , wherein:

the user settable real time threshold value defines an upper glucose value for a user;

the predictive threshold value defines an upper glucose value for the user; and

the first and second glycemic indicators are hyperglycemic indicators.

6 . The method of claim 1 , wherein:

the user settable real time threshold value defines a lower glucose value for a user;

the predictive threshold value defines a lower glucose value for the user; and

the first and second glycemic indicators are hypoglycemic indicators.

7 . A non-transitory computer-readable medium for storing instructions that, when executed by a processor, cause the processor to perform a method for activating glycemic indicators, the method comprising:

evaluating a selection of glucose sensor data using a first function to determine whether a real time glucose value meets or crosses a user settable real time threshold value;

evaluating the same selection of glucose sensor data using a second function different from the first function to determine whether a predicted glucose value meets or crosses a predictive threshold value within a fixed prediction horizon, wherein the user settable real time threshold value is different from the predictive threshold value;

providing a first output including a first glycemic indicator when the user settable real time threshold value is met or crossed; and

providing a second output including a second glycemic indicator when the predicted glucose value meets or crosses the predictive threshold value within the fixed prediction horizon.

8 . The non-transitory computer-readable medium of claim 7 , wherein the fixed prediction horizon is 20 minutes or less.

9 . The non-transitory computer-readable medium of claim 7 , wherein the fixed prediction horizon is not settable by a user.

10 . The non-transitory computer-readable medium of claim 7 , wherein the fixed prediction horizon is preset.

11 . The non-transitory computer-readable medium of claim 10 , wherein the fixed prediction horizon is preset at a factory.

12 . The non-transitory computer-readable medium of claim 10 , wherein:

the user settable real time threshold value defines an upper glucose value for a user;

the predictive threshold value defines an upper glucose value for the user; and

the first and second glycemic indicators are hyperglycemic indicators.

13 . The non-transitory computer-readable medium of claim 10 , wherein:

the user settable real time threshold value defines a lower glucose value for a user;

the predictive threshold value defines a lower glucose value for the user; and

the first and second glycemic indicators are hypoglycemic indicators.

14 . A system for activating glycemic indicators, the system comprising:

a memory configured to store glucose sensor data from a transcutaneous glucose sensor; and

a processor, coupled to the memory, the processor configured to:

evaluate a selection of the glucose sensor data using a first function to determine whether a real time glucose value meets or crosses a user settable real time threshold value,

evaluate the same selection of glucose sensor data using a second function different from the first function to determine whether a predicted glucose value meets or crosses a predictive threshold value within a fixed prediction horizon, wherein the user settable real time threshold value is different from the predictive threshold value,

provide a first output including a first glycemic indicator when the user settable real time threshold value is met or crossed, and

provide a second output including a second glycemic indicator when the predicted glucose value meets or crosses the predictive threshold value within the fixed prediction horizon.

15 . The system of claim 14 , wherein the fixed prediction horizon is 20 minutes or less.

16 . The system of claim 14 , wherein the fixed prediction horizon is not settable by a user.

17 . The system of claim 14 , wherein the fixed prediction horizon is preset at a factory.

18 . The system of claim 14 , wherein:

the user settable real time threshold value defines an upper glucose value for a user;

the predictive threshold value defines an upper glucose value for the user; and

the first and second glycemic indicators are hyperglycemic indicators.

19 . The system of claim 14 , wherein:

the user settable real time threshold value defines a lower glucose value for a user;

the predictive threshold value defines a lower glucose value for the user; and

the first and second glycemic indicators are hypoglycemic indicators.

20 . A method for activating glycemic indicators, the method comprising:

evaluating a selection of glucose sensor data to determine whether a real time glucose value meets or crosses a user settable real time threshold value, wherein the selection of glucose sensor data includes a value representative of one or more data points averaged over a predetermined time period;

evaluating the same selection of glucose sensor data to determine whether a predicted glucose value meets or crosses a predictive threshold value within a preset fixed prediction horizon, wherein the user settable real time threshold value is different from the predictive threshold value;

providing a first output including a first glycemic indicator when the user settable real time threshold value is met or crossed; and

providing a second output including a second glycemic indicator when the predicted glucose value meets or crosses the predictive threshold value within the preset fixed prediction horizon.

21 . A non-transitory computer-readable medium for storing instructions that, when executed by a processor, cause the processor to perform a method for activating glycemic indicators, the method comprising:

evaluating a selection of glucose sensor data to determine whether a real time glucose value meets or crosses a user settable real time threshold value, wherein the selection of glucose sensor data includes a value representative of one or more data points averaged over a predetermined time period;

evaluating the same selection of glucose sensor data to determine whether a predicted glucose value meets or crosses a predictive threshold value within a preset fixed prediction horizon, wherein the user settable real time threshold value is different from the predictive threshold value;

providing a first output including a first glycemic indicator when the user settable real time threshold value is met or crossed; and

providing a second output including a second glycemic indicator when the predicted glucose value meets or crosses the predictive threshold value within the preset fixed prediction horizon.

22 . A system for activating glycemic indicators, the system comprising:

a memory configured to store glucose sensor data from a transcutaneous glucose sensor; and

a processor, coupled to the memory, the processor configured to:

evaluate a selection of glucose sensor data to determine whether a real time glucose value meets or crosses a user settable real time threshold value, wherein the selection of glucose sensor data includes a value representative of one or more data points averaged over a predetermined time period;

evaluate the same selection of glucose sensor data to determine whether a predicted glucose value meets or crosses a predictive threshold value within a preset fixed prediction horizon, wherein the user settable real time threshold value is different from the predictive threshold value;

provide a first output including a first glycemic indicator when the user settable real time threshold value is met or crossed; and

provide a second output including a second glycemic indicator when the predicted glucose value meets or crosses the predictive threshold value within the preset fixed prediction horizon.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2023
From: BHAVARAJU, NARESH C.; HAMPAPURAM, HARI; KAMATH, APURV ULLAS; RACK-GOMER, ANNA LEIGH
To: DEXCOM, INC.
Reel/Frame 065294/0792 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2023
From: COBELLI, CLAUDIO; FACCHINETTI, ANDREA; SPARACINO, GIOVANNI; ZECCHIN, CHIARA
To: UNIVERSITA DEGLI STUDI DI PADOVA
Reel/Frame 065294/0894 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2023
From: UNIVERSITA DEGLI STUDI DI PADOVA
To: DEXCOM, INC.
Reel/Frame 065294/0981 →
Continuity (9)
Continuation 16884593 · May 27, 2020
Continuation 16674979 · Nov 5, 2019
Continuation 16172550 · Oct 26, 2018
Continuation 15486704 · Apr 13, 2017
Continuation 14720668 · May 22, 2015
Continuation 13742841 · Jan 16, 2013
Continuation 13742694 · Jan 16, 2013
Provisional Application 61720286 · Oct 30, 2012
Related Publication 20230210474A1 · Jul 6, 2023
References Cited (318)
US 65604A · Reynolds · 1867 [cited by applicant]
US 4431004A · Bessman et al. · 1984 [cited by applicant]
US 5299571A · Mastrototaro · 1994 [cited by applicant]
US 5390671A · Lord et al. · 1995 [cited by applicant]
US 5568806A · Cheney, II et al. · 1996 [cited by applicant]
US 5586553A · Halili et al. · 1996 [cited by applicant]
US 5680858A · Hansen et al. · 1997 [cited by applicant]
US 5851197A · Marano et al. · 1998 [cited by applicant]
US 5971922A · Arita et al. · 1999 [cited by applicant]
US 5993411A · Choi · 1999 [cited by applicant]
US 6093172A · Funderburk et al. · 2000 [cited by applicant]
US 6134461A · Say et al. · 2000 [cited by applicant]
US 6175752B1 · Say et al. · 2001 [cited by applicant]
US 6180416B1 · Kurnik et al. · 2001 [cited by applicant]
US 6197001B1 · Wilson et al. · 2001 [cited by applicant]
US 6212424B1 · Robinson · 2001 [cited by applicant]
US 6236872B1 · Diab et al. · 2001 [cited by applicant]
US 6254586B1 · Mann et al. · 2001 [cited by applicant]
US 6272364B1 · Kurnik · 2001 [cited by applicant]
US 6293925B1 · Safabash et al. · 2001 [cited by applicant]
US 6424847B1 · Mastrototaro et al. · 2002 [cited by applicant]
US 6479690B1 · Garel et al. · 2002 [cited by applicant]
US 6544212B2 · Galley et al. · 2003 [cited by applicant]
US 6546269B1 · Kurnik · 2003 [cited by applicant]
US 6553244B2 · Lesho et al. · 2003 [cited by applicant]
US 6558351B1 · Steil et al. · 2003 [cited by applicant]
US 6560471B1 · Heller et al. · 2003 [cited by applicant]
US 6565509B1 · Say et al. · 2003 [cited by applicant]
US 6572545B2 · Knobbe et al. · 2003 [cited by applicant]
US 6574490B2 · Abbink et al. · 2003 [cited by applicant]
US 6575905B2 · Knobbe et al. · 2003 [cited by applicant]
US 6577899B2 · Lebel et al. · 2003 [cited by applicant]
US 6579690B1 · Bonnecaze et al. · 2003 [cited by applicant]
US 6607509B2 · Bobroff et al. · 2003 [cited by applicant]
US 6653091B1 · Dunn et al. · 2003 [cited by applicant]
US 6656114B1 · Poulsen et al. · 2003 [cited by applicant]
US 6695860B1 · Ward et al. · 2004 [cited by applicant]
US 6740518B1 · Duong et al. · 2004 [cited by applicant]
US 6882940B2 · Potts et al. · 2005 [cited by applicant]
US 6895263B2 · Shin et al. · 2005 [cited by applicant]
US 6990366B2 · Say et al. · 2006 [cited by applicant]
US 6991619B2 · Marano-Ford et al. · 2006 [cited by applicant]
US 6991620B2 · Marano-Ford et al. · 2006 [cited by applicant]
US 6997907B2 · Safabash et al. · 2006 [cited by applicant]
US 7003336B2 · Holker et al. · 2006 [cited by applicant]
US 7003341B2 · Say et al. · 2006 [cited by applicant]
US 7022072B2 · Fox et al. · 2006 [cited by applicant]
US 7022108B2 · Marano-Ford et al. · 2006 [cited by applicant]
US 7029444B2 · Shin et al. · 2006 [cited by applicant]
US 7190988B2 · Say et al. · 2007 [cited by applicant]
US 7207974B2 · Safabash et al. · 2007 [cited by applicant]
US 7228162B2 · Ward et al. · 2007 [cited by applicant]
US 7282029B1 · Poulsen et al. · 2007 [cited by applicant]
US 7299082B2 · Feldman et al. · 2007 [cited by applicant]
US 7310544B2 · Brister et al. · 2007 [cited by applicant]
US 7318816B2 · Bobroff et al. · 2008 [cited by applicant]
US 7343188B2 · Sohrab · 2008 [cited by applicant]
US 7381184B2 · Funderburk et al. · 2008 [cited by applicant]
US 7384397B2 · Zhang et al. · 2008 [cited by applicant]
US 7389133B1 · Kotulla et al. · 2008 [cited by applicant]
US 7399277B2 · Saidara et al. · 2008 [cited by applicant]
US 7402153B2 · Steil et al. · 2008 [cited by applicant]
US 7494465B2 · Brister et al. · 2009 [cited by applicant]
US 7582059B2 · Funderburk et al. · 2009 [cited by applicant]
US 7602310B2 · Mann et al. · 2009 [cited by applicant]
US 7618369B2 · Hayter et al. · 2009 [cited by applicant]
US 7630748B2 · Budiman · 2009 [cited by applicant]
US 7647237B2 · Malave et al. · 2010 [cited by applicant]
US 7653425B2 · Hayter et al. · 2010 [cited by applicant]
US 7654956B2 · Brister et al. · 2010 [cited by applicant]
US 7660615B2 · Vanantwerp et al. · 2010 [cited by applicant]
US 7670288B2 · Sher · 2010 [cited by applicant]
US 7682338B2 · Griffin · 2010 [cited by applicant]
US 7686787B2 · Moberg et al. · 2010 [cited by applicant]
US 7695434B2 · Malecha · 2010 [cited by applicant]
US 7697967B2 · Stafford · 2010 [cited by applicant]
US 7699807B2 · Faust et al. · 2010 [cited by applicant]
US 7704229B2 · Moberg et al. · 2010 [cited by applicant]
US 7729737B2 · Ward · 2010 [cited by applicant]
US 7731657B2 · Stafford · 2010 [cited by applicant]
US 7731659B2 · Malecha · 2010 [cited by applicant]
US 7736310B2 · Taub · 2010 [cited by applicant]
US 7736338B2 · Kavazov et al. · 2010 [cited by applicant]
US 7736344B2 · Moberg et al. · 2010 [cited by applicant]
US 7740613B2 · Yokoi et al. · 2010 [cited by applicant]
US 7744589B2 · Mounce et al. · 2010 [cited by applicant]
US 7762793B2 · Gray et al. · 2010 [cited by applicant]
US H2246H · Miller et al. · 2010 [cited by applicant]
US 7766830B2 · Fox et al. · 2010 [cited by applicant]
US 7768386B2 · Hayter et al. · 2010 [cited by applicant]
US 7771393B2 · Liniger et al. · 2010 [cited by applicant]
US 7774038B2 · Wang et al. · 2010 [cited by applicant]
US 7783442B2 · Mueller, Jr. et al. · 2010 [cited by applicant]
US 7785293B2 · Gray et al. · 2010 [cited by applicant]
US 7789857B2 · Moberg et al. · 2010 [cited by applicant]
US 7815569B2 · Kovatchev et al. · 2010 [cited by applicant]
US 7815607B2 · Rutti et al. · 2010 [cited by applicant]
US 7846132B2 · Gravesen et al. · 2010 [cited by applicant]
US 7850652B2 · Liniger et al. · 2010 [cited by applicant]
US 7860544B2 · Say et al. · 2010 [cited by applicant]
US 7866026B1 · Wang et al. · 2011 [cited by applicant]
US 7869853B1 · Say et al. · 2011 [cited by applicant]
US 7871394B2 · Halbert et al. · 2011 [cited by applicant]
US 7878975B2 · Liljeryd et al. · 2011 [cited by applicant]
US 7885698B2 · Feldman · 2011 [cited by applicant]
US 7890295B2 · Shin et al. · 2011 [cited by applicant]
US 7895740B2 · Wang et al. · 2011 [cited by applicant]
US 7899545B2 · John · 2011 [cited by applicant]
US 7912655B2 · Power et al. · 2011 [cited by applicant]
US 7912674B2 · Killoren Clark et al. · 2011 [cited by applicant]
US 7920907B2 · McGarraugh et al. · 2011 [cited by applicant]
US 7946985B2 · Mastrototaro et al. · 2011 [cited by applicant]
US 7970449B2 · Ward · 2011 [cited by applicant]
US 7976466B2 · Ward et al. · 2011 [cited by applicant]
US 7981034B2 · Jennewine et al. · 2011 [cited by applicant]
US 7988630B1 · Osorio et al. · 2011 [cited by applicant]
US 7996158B2 · Hayter et al. · 2011 [cited by applicant]
US 8103456B2 · Doniger et al. · 2012 [cited by applicant]
US 8103471B2 · Hayter · 2012 [cited by applicant]
US 8129173B2 · Shapiro et al. · 2012 [cited by applicant]
US 8135548B2 · Breton et al. · 2012 [cited by applicant]
US 8219173B2 · Budiman et al. · 2012 [cited by applicant]
US 8224415B2 · Budiman · 2012 [cited by applicant]
US 8260558B2 · Hayter et al. · 2012 [cited by applicant]
US 8273022B2 · Say et al. · 2012 [cited by applicant]
US 9119528B2 · Cobelli · 2015 [cited by examiner]
US 9119529B2 · Hampapuram et al. · 2015 [cited by applicant]
US 9655565B2 · Hampapuram et al. · 2017 [cited by applicant]
US 10143426B2 · Hampapuram et al. · 2018 [cited by applicant]
US 10555705B2 · Hampapuram et al. · 2020 [cited by applicant]
US 10702215B2 · Hampapuram et al. · 2020 [cited by applicant]
US 11690577B2 · Hampapuram · 2023 [cited by examiner]
US 20050004439A1 · Shin et al. · 2005 [cited by applicant]
US 20050027182A1 · Siddiqui et al. · 2005 [cited by applicant]
US 20050033254A1 · Fell et al. · 2005 [cited by applicant]
US 20050038332A1 · Saidara et al. · 2005 [cited by applicant]
US 20050177035A1 · Botvinick et al. · 2005 [cited by applicant]
US 20060276771A1 · Galley et al. · 2006 [cited by applicant]
US 20070208244A1 · Brauker · 2007 [cited by examiner]
US 20080033254A1 · Kamath et al. · 2008 [cited by applicant]
US 20080103447A1 · Reggiardo et al. · 2008 [cited by applicant]
US 20080119710A1 · Reggiardo et al. · 2008 [cited by applicant]
US 20080188731A1 · Brister et al. · 2008 [cited by applicant]
US 20080234992A1 · Ray et al. · 2008 [cited by applicant]
US 20080314395A1 · Kovatchev et al. · 2008 [cited by applicant]
US 20090005666A1 · Shin et al. · 2009 [cited by applicant]
US 20090030641A1 · Fjield et al. · 2009 [cited by applicant]
US 20090105636A1 · Hayter et al. · 2009 [cited by applicant]
US 20090160656A1 · Seetharaman et al. · 2009 [cited by applicant]
US 20090192380A1 · Shariati · 2009 [cited by examiner]
US 20090275815A1 · Bickoff et al. · 2009 [cited by applicant]
US 20100057042A1 · Hayter · 2010 [cited by applicant]
US 20100137699A1 · Sher · 2010 [cited by applicant]
US 20100191472A1 · Doniger et al. · 2010 [cited by applicant]
US 20100198314A1 · Wei · 2010 [cited by applicant]
US 20110021898A1 · Wei · 2011 [cited by examiner]
US 20110077494A1 · Doniger et al. · 2011 [cited by applicant]
US 20110098548A1 · Budiman et al. · 2011 [cited by applicant]
US 20110106011A1 · Cinar et al. · 2011 [cited by applicant]
US 20110184265A1 · Hayter · 2011 [cited by examiner]
US 20110184267A1 · Duke et al. · 2011 [cited by applicant]
US 20110193704A1 · Harper · 2011 [cited by examiner]
US 20110225112A1 · Cameron et al. · 2011 [cited by applicant]
US 20130109944A1 · Sparacino · 2013 [cited by examiner]
US 20140012511A1 · Mensinger et al. · 2014 [cited by applicant]
US 20140118138A1 · Cobelli et al. · 2014 [cited by applicant]
US 20140118166A1 · Hampapuram et al. · 2014 [cited by applicant]
US 20150250429A1 · Hampapuram et al. · 2015 [cited by applicant]
US 20170224291A1 · Hampapuram et al. · 2017 [cited by applicant]
US 20190059826A1 · Hampapuram et al. · 2019 [cited by applicant]
US 20200060630A1 · Hampapuram et al. · 2020 [cited by applicant]
US 20200138385A1 · Hampapuram et al. · 2020 [cited by applicant]
US 20200281541A1 · Hampapuram et al. · 2020 [cited by applicant]
CN 101278847A · 2008 [cited by applicant]
CN 101534704A · 2009 [cited by applicant]
CN 102334113A · 2012 [cited by applicant]
CN 109480861B · 2022 [cited by applicant]
EP 1102559B1 · 2003 [cited by applicant]
EP 1077634B1 · 2003 [cited by applicant]
EP 1078258B1 · 2003 [cited by applicant]
EP 1119637B1 · 2004 [cited by applicant]
EP 1144028B1 · 2004 [cited by applicant]
EP 1503660B1 · 2007 [cited by applicant]
EP 1437674B1 · 2008 [cited by applicant]
EP 1706022B1 · 2008 [cited by applicant]
EP 1473050B1 · 2009 [cited by applicant]
EP 1518495B1 · 2010 [cited by applicant]
EP 2051620B1 · 2010 [cited by applicant]
EP 1759201B1 · 2010 [cited by applicant]
EP 2069771B1 · 2011 [cited by applicant]
EP 1927602B1 · 2012 [cited by applicant]
EP 1703839B1 · 2012 [cited by applicant]
EP 1890597B1 · 2012 [cited by applicant]
EP 1931253B1 · 2012 [cited by applicant]
EP 3782539B1 · 2021 [cited by applicant]
WO 9958051A1 · 1999 [cited by applicant]
WO 02082989A1 · 2002 [cited by applicant]
WO 2005065538A2 · 2005 [cited by applicant]
WO 2005121785A2 · 2005 [cited by applicant]
WO 2008042918A2 · 2008 [cited by applicant]
WO 2009136372A1 · 2009 [cited by applicant]
WO 2011051922A2 · 2011 [cited by applicant]
WO 2013090731A1 · 2013 [cited by applicant]
WO 2013128912A1 · 2013 [cited by applicant]
WO 2014011488A2 · 2014 [cited by applicant]
WO 2014070456A1 · 2014 [cited by applicant]
Arnold M., et al., “Adaptive AR Modeling of Nonstationary by Means of Kalman Filtering,” IEEE Transactions on Biomedical Engineering, vol. 45(5), 1998, pp. 553-562. [cited by applicant]
Australia and New Zealand Horizon Scanning Network, “GlucoWatch G2 Biographer for the Non-Invasive Monitoring of Glucose Levels,” National Horizon Scanning Unit, Horizon Scanning Report, May 2004, 46 pages. [cited by applicant]
Bindra., et al., “Design and in vitro studies of a needle-type glucose sensor for subcutaneous monitoring,” Anal Chem., 1991, vol. 63(17), pp. 1692-1696. [cited by applicant]
Bremer T., et al., “Is Blood Glucose Predictable from Previous Values? A Solicitation for Data,” Perspectives in Diabetes, vol. 48, Mar. 1999, pp. 445-451. [cited by applicant]
Brief communication for European Patent Application No. 13784079.9, dated Apr. 1, 2022, 5 pages. [cited by applicant]
Brief communication for European Patent Application No. 13784079.9, dated Aug. 8, 2022, 42 pages. [cited by applicant]
Brief communication for European Patent Application No. 13784079.9, dated Nov. 10, 2022, 12 pages. [cited by applicant]
Brief communication for European Patent Application No. 13784079.9, dated Nov. 29, 2022, 21 pages. [cited by applicant]
Brief communication for European Patent Application No. 13784079.9, dated Oct. 13, 2022, 46 pages. [cited by applicant]
Brief Communication for European Patent Application No. 20190682.3, dated Dec. 21, 2022, 98 pages. [cited by applicant]
Brief Communication for European Patent Application No. 20190682.3, dated Jan. 20, 2023, 58 pages. [cited by applicant]
Brief Communication for European Patent Application No. 20190682.3, dated Nov. 16, 2022, 2 pages. [cited by applicant]
Brief communication for European Patent Application No. 20190682.3, dated Oct. 10, 2022, 70 pages. [cited by applicant]
Cass et al., “Ferrocene-Mediated Enzyme Electrode for Amperometric Determination of Glucose,” Anal. Chem. Soc., 1984, vol. 56(4), pp. 667-671. [cited by applicant]
Chaudhary et al., “Insulin Pump Therapy With Automated Insulin Suspension in Response to Hypoglycemia,” Diabetes Care, Sep. 2011, vol. 34, pp. 2023-2025. [cited by applicant]
Choleau C., et al., “Calibration of a Subcutaneous Amperometric Glucose Sensor Implanted for 7 Days in Diabetic Patients Part 2. Superiority of the One-point Calibration Method,” Biosensors and Bioelectronics, vol. 17 (… [cited by applicant]
Choleau C., et al., “Calibration of a Subcutaneous Amperometric Glucose Sensor Part 1. Effect of Measurement Uncertainties on the Determination of Sensor Sensitivity and Background Current,” Biosensors and Bioelectronic… [cited by applicant]
Citation in opposition procedure—041 for European Patent Application No. 20190682.3, dated Jan. 16, 2023, 1 page. [cited by applicant]
Clarke W., et al., “Statistical Tools to Analyze Continuous Glucose Monitor Data,” Diabetes Technology Therapeutics, Jun. 2009, vol. 11, Supplement 1, pp. S45-S54. [cited by applicant]
Clemens A.H., et al., “Development of the Biostator® Glucose Clamp Algorithm,” Artificial Systems for Insulin Delivery, vol. 6, pp. 399-409 (edited by P. Brunetti et al. ed., 1983). [cited by applicant]
Close K., “Test Driving Dexcom's Short-Term Sensor (STS): A Look at Continuous Glucose Monitoring,” diatribe Learn, Dec. 31, 2006, Retrieved from the Internet: https://diatribe.org/test-driving-dexcoms-short-term-sensor… [cited by applicant]
Commenges D., “The Deconvolution Problem: Fast Algorithms Including the Preconditioned Conjugate-Gradient to Compute a MAP Estimator,” IEEE Transaction on Automatic Control, vol. 29(3), 1984, pp. 229-243. [cited by applicant]
Communication of a Notice of Opposition for European Patent Application No. 13784079.9, dated Jan. 21, 2022, 168 pages. [cited by applicant]
Communication of a Notice of Opposition for European Patent Application No. 13784079.9, dated Oct. 13, 2021, 128 pages. [cited by applicant]
Communication of a notice of opposition for European Patent Application No. 20190682.3, dated Mar. 15, 2022, 153 pages. [cited by applicant]
Communication of a notice of opposition for European Patent Application No. 20190682.3, dated Mar. 15, 2022, 50 pages. [cited by applicant]
Communication of a notice of opposition for European Patent Application No. 20190682.3, dated Oct. 12, 2021, 107 pages. [cited by applicant]
Communication of a notice of opposition from European application No. 13784079.9, mailed Jan. 24, 2022, 1 page. [cited by applicant]
Communication of further notices of opposition pursuant to Rule 79(2) EPC for European Patent Application No. 13784079.9, dated Jan. 25, 2022, 148 pages. [cited by applicant]
Communication of further notices of opposition pursuant to Rule 79(2) EPC for European Patent Application No. 13784079.9, dated Jan. 25, 2022, 152 pages. [cited by applicant]
Communication of further notices of opposition pursuant to Rule 79(2) EPC for European Patent Application No. 20190682.3, dated Mar. 23, 2022, 158 pages. [cited by applicant]
Communication of further notices of opposition pursuant to Rule 79(2) EPC for European Patent Application No. 20190682.3, dated Mar. 23, 2022, 204 pages. [cited by applicant]
Communication of further notices of opposition pursuant to Rule 79(2) EPC for European Patent Application No. 20190682.3, dated Mar. 23, 2022, 261 pages. [cited by applicant]
“Congressional Record: Urging FDA to Act Promptly Tapprove Artificial Pancreas Technologies,” retrieved on [Feb. 22, 2022], Retrieved from the Internet: https://www.congress.gov/help/congressional-record, 3 pages. [cited by applicant]
Consolidated list of cited opposition documents for European Patent Application No. 20190682.3, dated Jan. 16, 2023, 2 pages. [cited by applicant]
Cunningham D.D., et al., “In Vivo Glucose Sensing,” Chemical Analysis, 2010, vol. 174, 466 pages. [cited by applicant]
Dassau E., et al., “Real-Time Hypoglycemia Prediction Suite Using Continuous Glucose Monitoring,” Emerging Treatment and Technologies, Diabetes Care, vol. 33 (6), Jun. 2010, pp. 1249-1254. [cited by applicant]
De Nicolao G., et al., “Nonparametric Input Estimation in Physiological Systems: Problems, Methods and Case Studies,” Automatica, vol. 33(5), 1997, pp. 851-870. [cited by applicant]
DEXCOM, “DexCom STS Continuous Glucose Monitoring System User's Guide,” DexCom, 2006, pp. 1-112. [cited by applicant]
DEXCOM Inc., “Defendant's Preliminary Invalidity Contentions,” Civil Action No. 6:21-cv-00690-ADA, Jan. 25, 2022, 239 pages. [cited by applicant]
DexCoM Inc., “DexCom Receives FDA Approval For STS™ Continuous Glucose Monitoring System,” STS Press Release, Mar. 27, 2006, https://dexcom.gcs-web.com/news-releases/news-release-details/dexcom-receives-fda-approval-sts… [cited by applicant]
DexCoM Inc., “Summary of Safety and Effectiveness Data,” DexCom™ STS™ Continuous Glucose Monitoring System, Mar. 24, 2006, 20 pages. [cited by applicant]
“DexCom STS-7 Summary of Safety and Effectiveness Data”, 2007, 14 pages. [cited by applicant]
DexCom “STS@-7 Continuous Glucose Monitoring System User's guide,” Retrieved from Internet URL: https://www.accessdata.fda.gov/cdrh_docs/pdf5/P050012S001c.pdf, 2007, 74 pages. [cited by applicant]
Diabetes Research in Children Network (DirecNet) Study Group, “GlucoWatch G2 Biographer (GW2B) Alarm Reliability During Hypoglycemia in Children,” Diabetes Technology and Therapeutics, Oct. 2004, vol. 6(5), 12 pages. [cited by applicant]
Eren-Oruklu M., et al., “Estimation of Future Glucose Concentrations with Subject-Specific Recursive Linear Models,” Diabetes Technology Therapeutics, vol. 11 (4), 2009, pp. 243-253. [cited by applicant]
Eren-Oruklu M., et al., “Hypoglycemia Prediction with Subject-Specific Recursive Time-Series Models,” Journal of Diabetes Science and Technology, vol. 4(1), Jan. 2010, pp. 25-33. [cited by applicant]
Facchinetti A., et al., “An Online Self-Tunable Method to Denoise CGM Sensor Data,” IEEE Transactions on Biomedical engineering, vol. 57 (3), Mar. 1, 2010, pp. 634-641. [cited by applicant]
Facchinetti A., et al., “Online Denoising Method to Handle Intra-Individual Variability of Signal-to-Noise Ratio in Continuous Glucose Monitoring,” IEEE Trans Biomed Eng (BME), vol. 58(9), 2011, pp. 2664-2671. [cited by applicant]
Facchinetti et al., “A New Index to Optimally Design and Compare Continuous Glucose Monitoring Glucose Prediction Algorithms,” Diabetes Technology & Therapeutics, 2011, vol. 13, No. 2, pp. 111-119. [cited by applicant]
Sandham W., et al., “Blood Glucose Prediction for Diabetes Therapy Using a Recurrent Artificial Neural Network,”, IX European Signal Processing Conference, 1998, pp. 673-676. [cited by applicant]
Sparacino G., et al., “A Stochastic Deconvolution Method to Reconstruct Insulin Secretion Rate After a Glucose Stimulus,” IEEE Transaction on Biomedical Engineering, May 1996, vol. 43(5), pp. 512-529. [cited by applicant]
Sparacino G., et al., “Glucose Concentration Can Be Predicted Ahead in Time From Continuous Glucose Monitoring Sensor Time-Series,” IEEE Transactions on Biomedical Engineering, May 2007, vol. 54(5), pp. 931-937. [cited by applicant]
Summons to attend Oral Proceedings pursuant to Rule 115 (1) EPC for European Application No. 13784079.9, dated Jan. 26, 2023, 12 pages. [cited by applicant]
Tarvainen M.P., et al., “Estimates of Non Stationary EEG with Kalman Smoother Approach: An Application to Event-Related Synchronization (ERS),” IEEE Transactions on Biomedical Engineering, Mar. 2004, vol. 51(3), pp. 516… [cited by applicant]
The Dexcom G4 CGM System, “OUS Commercialization Agreement,” Exhibit 10.2, available at https://www.sec.gov/Archives/edgar/data/1093557/000119312509012580/dex102.htm, Jan. 12, 2009, 49 pages. [cited by applicant]
“TheraSense Files Premarket Approval Application for Freestyle Navigator(TM) Cont,” Diabetes In Control, Dec. 13, 2003, Retrieved from the Internet: https://www.diabetesincontrol.com/therasense-files-premarket-approval-… [cited by applicant]
Tikhonov A.N, “Solution of Incorrectly Formulated Problems and the Regularization Method,” Soviet Method Dokl, vol. 4, 1963, pp. 1035-1038. [cited by applicant]
Wikipedia, “Spectral Density,” retrieved from http://en.wikipedia.org/wiki/Spectral_density, on Jan. 29, 2013, 8 pages. [cited by applicant]
FDA: “Freestyle Navigator Continuous Glucose Monitor”, [cited Sep. 14, 2022] Available from: [https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?ID=P050020], 6 pages. [cited by applicant]
FDA: “PMA Approvals,” retrieved on [Oct. 18, 2006], Available from: https://www.fda.gov/medical-devices/device-approvals-denials-and-clearances/pma-approvals, 4 pages. [cited by applicant]
Federal Register: “Draft Guidance for Industry and Food and Drug Administration Staff: The Content of Investigational Device Exemption and Premarket Approval Applications for Low Glucose Suspend Device Systems; Availabi… [cited by applicant]
Fogt E.J., et al., “Development and Evaluation of a Glucose Analyzer for a Glucose-Controlled Insulin Infusion System (Biostator),” Clinical Chemistry, vol. 24, No. 08, Retrieved from Internet URL: https://citeseerx.ist… [cited by applicant]
Freeland A.C., et al., “Inference of Blood Glucose Concentrations from Subcutaneous Glucose Concentrations: Applications to Glucose Biosensors,” Annals of Biomedical Engineering, 1999, vol. 27, pp. 525-537. [cited by applicant]
Gani A., et al., “Predicting Subcutaneous Glucose Concentration in Humans: Data-Driven Glucose Modeling,” IEEE Transactions on Biomedical Engineering, vol. 56(2), Feb. 2009, pp. 246-254. [cited by applicant]
Gani A., et al., “Universal Glucose Models for Predicting Subcutaneous Glucose Concentration in Humans,” IEEE Transactions on Information Technology in Biomedicine, vol. 14(1), Jan. 2010, pp. 157-165. [cited by applicant]
Garg et at., “Improved Glucose Excursions Using an Implantable Real-Time Continuous Glucose Sensor in Adults With Type 1 Diabetes,” Diabetes Care, 2004, vol. 27, pp. 734-738. [cited by applicant]
Garg S., et al. “Improvement in Glycemic Excursions with a Transcutaneous, Real-Time Continuous Glucose Sensor: A Randomized Controlled Trial,” Diabetes Care, vol. 29(1), 2006, pp. 44-50. [cited by applicant]
Guerra S., et al., “A Dynamic Risk Measure from Continuous Glucose Monitoring Data,” Diabetes Technology & Therapeutics, 2011, vol. 13(8), pp. 843-852. [cited by applicant]
Guerra S., et al., “Enhancing the Accuracy of Subcutaneous Glucose Sensors: A Real-Time Deconvolution-Based Approach,” IEEE Transactions on Biomedical Engineering, vol. 59(6), Jun. 2012, pp. 1658-1669. [cited by applicant]
Hanlon., “DexCom's 7-Day STS Continuous Glucose Monitoring System,” 2007, 1 page. [cited by applicant]
Hayter et at., “Performance Standards for Continuous Glucose Monitors,” Diabetes Technology Therapeutics, 2005, vol. 7, No. 5, pp. 721-726. [cited by applicant]
Heinemann L., et al., “Glucose Clamps with the Biostator: A Critical Reappraisal,” Hormone and Metabolic Research, Jan. 1995, vol. 26(12), 6 pages. [cited by applicant]
Heller A., et al., “Electrochemical Glucose Sensors and Their Applications in Diabetes Management,” Chemical Reviews, May 9, 2008, vol. 108, No. 6 pp. 2482-2505. [cited by applicant]
Heller A., “Integrated Medical Feedback Systems for Drug Delivery,” AlChE Journal, Apr. 2005, vol. 51, No. 4, pp. 1054-1066. [cited by applicant]
Hermanns N., et al., “The Impact of Continuous Glucose Monitoring on Low Interstitial Glucose Values and Low Blood Glucose Values Assessed by Point-Of-Care Blood Glucose Meters: Results of a Crossover Trial,” Journal of… [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2013/065244 mailed May 14, 2015, 14 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2013/065244 mailed Feb. 18, 2014, 19 pages. [cited by applicant]
King A.B., et al., “A Prospective Evaluation of Insulin Dosing Recommendations in Patients with Type 1 Diabetes at Near Normal Glucose Control: Basal Dosing,” Journal of Diabetes Science and Technology, Jan. 2007, vol. … [cited by applicant]
Kovatchev B.P., et al., “Risk Analysis of Blood Glucose Data: A Quantitative Approach to Optimizing the Control on Insulin Dependent Diabetes,” Journal of Theoretical Medicine, 2000, vol. 3, pp. 1-10. [cited by applicant]
“Description and Claims” with title Systems and Methods for Providing Sensitive and Specific Alarms, 103 pages. [cited by applicant]
“DexCom STS Sensor-Instruction for Use,” 2006, 6 pages. [cited by applicant]
“DexCom STS-User's Guide and Declaration,” 2007, 64 pages. [cited by applicant]
“DexCom Webpage,” retrieved on [Jul. 21, 2021], Retrieved from the Internet: https://www.dexcom.com/about-dexcom, 12 pages. [cited by applicant]
“Feature Analysis,” 1 page. [cited by applicant]
“FreeStyle Navigator Continuous Glucose Monitoring System,” User's Guide, 2008, 196 pages. [cited by applicant]
“FreeStyle Navigator FDA letter,” Mar. 12, 2008, 3 pages. [cited by applicant]
“FreeStyle Navigator 'Summary of Safety and Effectiveness Data,” 2008, 27 pages. [cited by applicant]
“International Standard CEI IEC 60601-1-8,” Second Edition, 2006, 166 pages. [cited by applicant]
“Letter containing the patentee's admissions regarding the date of the Dexcom STS Guide,” Jun. 7, 2022, 2 pages. [cited by applicant]
“Letter containing the patentee's admissions regarding the date of the STS-7 Guide,” Sep. 6, 2022, 7 pages. [cited by applicant]
“US Congress webpage extract,” Bound Edition, 2011, retrieved from the Internet: https://www.congress.gov/help/congressional-record, 3 pages. [cited by applicant]
Leal Y., et al., “Real-Time Glucose Estimation Algorithm for Continuous Glucose Monitoring Using Autoregressive Models,” Journal of Diabetes Science and Technology, vol. 4(2), Mar. 2010, pp. 391-403. [cited by applicant]
Letter from EPO dated Aug. 11, 2020 for the application No. 13784079.9, 2 pages. [cited by applicant]
Lu Y., et al., “The Importance of Different Frequency Bands in Predicting Subcutaneous Glucose Concentration in Type 1 Diabetic Patients,” IEEE Transactions on Biomedical Engineering, vol. 57(8), Aug. 2010, pp. 1839-184… [cited by applicant]
McMurry Jr J.F., “The Artificial Pancreas Today,” Henry Ford Hospital Medical Journal, Retrieved from Internet URL: https://scholarlycommons.henryford.com/cgi/viewcontent.cgi?article=2228context=hfhmedjournal, Retrieved… [cited by applicant]
Medtronic Minimed., “Continuous Glucose Monitoring System,” Clinical Chemistry, Retrieved from Internet URL: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P980022, Received on Dec. 15, 1997, 1 page. [cited by applicant]
Palerm C.C et al., “Hypoglycemia Detection and Prediction Using Continuous Glucose Monitoring—A Study on Hypoglycemic Clamp Data,” Journal of Diabetes Sciences and Technology, Sep. 2007, vol. 1(5), pp. 624-629. [cited by applicant]
Panteleon A.E., et al., “The Role of the Independent Variable to Glucose Sensor Calibration,” Diabetes Technology Therapeutics, vol. 5 (3), 2003, pp. 401-410. [cited by applicant]
Perez-Gandia C., et al., “Artificial Neural Network Algorithm for On-line Glucose Prediction from Continuous Glucose Monitoring,” Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), … [cited by applicant]
Phillips D.L., “A Technique for the Numerical Solution of Certain Integral Equations of the First Kind,” J. Assoc. Comput. Mach., 1962, vol. 9, pp. 84-97. [cited by applicant]
PMA Label, “Biostator Glucose Controller,” Retrieved from Internet URL: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P790028, Nov. 16, 1979, 3 pages. [cited by applicant]
PMA Label, “Dexcom STS Continuous Glucose Monitoring System,” Retrieved from Internet URL: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?ID=P050012, Mar. 23, 2005, 8 pages. [cited by applicant]
PMA Label, “Freestyle Navigator Continuous Glucose Monitor,” Retrieved from Internet URL: www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P050020, Jun. 8, 2005, 6 pages. [cited by applicant]
PMA Label, “Glucowatch G2, Automatic Glucose Biographer and Autosensors,” Retrieved from Internet URL: https://www.accessdata.fda.gov/cdrh_docs/pdf/P990026S008C.pdf, retrieved on Jun. 21, 2002, 70 pages. [cited by applicant]
PMA Label, “Glucowatch G2 Automatic Glucose Biographer,” Retrieved from Internet URL: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P990026S008, Sep. 19, 2001, 4 pages. [cited by applicant]
Rebrin K., et al., “Use of Subcutaneous Interstitial Fluid Glucose to Estimate Blood Glucose: Revisiting Delay and Sensor Offset,” Journal of Diabetes Science and Technology, Sep. 2010, vol. 4(5), pp. 1087-1098. [cited by applicant]
Reifman J., et al., “Predictive Monitoring for Improved Management of Glucose Levels,” Journal of Diabetes Science and Technology, Jul. 2007, vol. 1(4), pp. 478-486. [cited by applicant]
Request for Trial Granted for U.S. Appl. No. 16/674,979 dated Nov. 2, 2022, 31 pages. [cited by applicant]
Description and Claims of (EP20190682.3), 103 pages. [cited by applicant]
Feature analysis of (EP20190682.3), 1 page. [cited by applicant]
Letter from EPO for (EP13784079.9) dated Aug. 11, 2020, 2 pages. [cited by applicant]